

Phone app linked to improved psoriasis treatment adherence

April 23 2018



(HealthDay)—A smartphone app is associated with improved short-term

adherence to a cutaneous foam treatment for psoriasis, according to a study published online April 14 in the *British Journal of Dermatology*.

Mathias Tiedemann Svendsen, M.D., from Odense University Hospital in Denmark, and colleagues randomized 122 patients who were receiving once-daily medication (calcipotriol/betamethasone dipropionate [Cal/BD] cutaneous foam) to either no app (66 patients) or an app intervention (68 patients).

The researchers found that at week four, more patients in the intervention group were adherent to Cal/BD cutaneous foam versus [patients](#) in the non-intervention group (65 versus 38 percent: $P = 0.004$). The [intervention](#) group also showed a greater reduction in psoriasis severity, as measured by the Lattice System Physician's Global Assessment, versus the non-[intervention group](#) at week four ($P = 0.047$). While not reaching statistical significance, a similar effect was seen at weeks eight and 26.

"The app significantly improved adherence rates and reduced psoriasis severity in the short-term," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including LEO Pharma, which supported the study.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Phone app linked to improved psoriasis treatment adherence (2018, April 23) retrieved 2 May 2024 from <https://medicalxpress.com/news/2018-04-app-linked-psoriasis-treatment-adherence.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.